The extent of minimal residual disease reduction after the first 4‐week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia

BACKGROUND: Previously, the authors demonstrated the positive impact of imatinib on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph‐positive ALL). Here, the authors analyzed for risk factors that affect transplantat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2009-02, Vol.115 (3), p.561-570
Hauptverfasser:	Lee, Seok, Kim, Yoo‐Jin, Chung, Nak‐Gyun, Lim, Jihyang, Lee, Dong‐Gun, Kim, Hee‐Je, Min, Chang‐Ki, Lee, Jong‐Wook, Min, Woo‐Sung, Kim, Chun‐Choo
Format:	Artikel
Sprache:	eng
Schlagworte:	Abl protein Acute lymphatic leukemia Adolescent Adult allogeneic stem cell transplantation BCR protein Benzamides Biological and medical sciences Cancer Cell survival Disease-Free Survival Female Follow-Up Studies Fusion protein Humans Imatinib Imatinib Mesylate Male Medical sciences Middle Aged minimal residual disease Neoplasm, Residual - diagnosis Philadelphia chromosome‐positive acute lymphoblastic leukemia Piperazines - therapeutic use Polymerase chain reaction Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Prognosis Pyrimidines - therapeutic use Recurrence Remission Risk Factors Stem Cell Transplantation Survival Time Factors Transcription Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!